Upper gastrointestinal complications induced by anti-platelet agents

Area of Science:

• Gastroenterology
• Cardiology
• Pharmacology

Background:

• Low-dose aspirin and thienopyridine are widely used for cardiovascular disease prevention.
• These anti-platelet agents are associated with significant gastrointestinal (GI) complications, including bleeding, ulceration, and perforation.
• Endoscopic studies reveal a higher prevalence of GI ulcers than previously reported in observational studies.

Purpose of the Study:

• To review the incidence and risk factors of GI complications associated with anti-platelet therapy.
• To summarize current prevention strategies for GI bleeding in patients taking low-dose aspirin.
• To highlight the need for further research to determine optimal GI protection strategies, particularly in the Japanese population.

Main Methods:

• Systematic review of existing literature on aspirin and thienopyridine-induced GI complications.
• Analysis of data from clinical trials (HOT study, PPP study) and endoscopic evaluations.
• Identification and synthesis of reported risk factors and preventive measures.

Main Results:

• GI bleeding incidence in aspirin groups was reported around 0.76-0.82% in major trials.
• Endoscopic evaluation showed a higher prevalence of GI ulcers (11%) in patients on low-dose aspirin for cardiovascular prevention.
• Identified risk factors include prior GI bleeding, advanced age, H. pylori infection, and concurrent use of NSAIDs or other anti-platelet agents.

Conclusions:

• Anti-platelet therapy poses a considerable risk of GI complications.
• Current prevention strategies involve pharmacologic interventions such as proton pump inhibitors and H. pylori eradication.
• Further investigation is crucial to tailor effective GI protection strategies for diverse patient populations, including those in Japan.